At 4 h post dose (day 0), both molecules significantly reduced glucose excursion, but only MEDI4166 reduced glucose excursion at day 10 (Supplementary Fig
This launch obligation mechanism has drawn sharp criticism from EFPIA, which modeled the impact at a loss of approximately 15-20 NMEs per decade for European patients due to reduced R&D investment incentives
Its no wonder that, since this new class of appetite-curbing GLP-1 medications, including Ozempic, Wegovy, and Zepbound, burst into public consciousness, nearly $1 billion of venture capital dollars have been injected into the growing sector of weight-loss companies, which is now awash with startups prescribing the drugs, according to PitchBook data from the last year and a half
Additionally, there is an immediate demand for the creation and application of reliable, standardized biomarkers of aging to assess therapeutic effectiveness not through clinical indicators of metabolic regulation, but through biological aging
At the same time, Medicaid programs in some states have begun covering GLP-1s for weight loss , recognizing obesity as a serious health condition that leads to higher long-term healthcare costs
